Review urges a multiorgan view of canine heart failure

Version 2

A newly published review is pushing veterinary cardiology toward a broader view of heart failure. In Veterinary Sciences, authors Mitsuhiro Isaka, Hiromu Udagawa, Yuji Hamamoto, and Eunryel Nam argue that canine heart failure should be reframed as a multiorgan network disorder rather than a disease defined mainly by impaired myocardial contractility. Published April 29, 2026, the paper highlights naturally occurring canine heart failure, particularly myxomatous mitral valve disease and dilated cardiomyopathy, as a useful real-world and translational model for studying how systemic dysfunction unfolds over time. (mdpi.com)

That argument builds on a longer arc in both human and veterinary medicine. Human cardiology has increasingly emphasized cardiorenal, cardiointestinal, and neurohormonal interactions in heart failure, while veterinary medicine has already established a framework for cardiovascular-renal disorders in dogs and cats through a consensus statement published in the Journal of Veterinary Internal Medicine. That statement underscored that dysfunction in the heart, vasculature, and kidneys often progresses bidirectionally, even if the evidence base remains incomplete. The new review extends that logic, suggesting veterinary cardiology now needs a more integrated framework that captures additional organ systems and signaling networks. (pmc.ncbi.nlm.nih.gov)

The review outlines four major axes of interaction: the heart-gut axis, the heart-bone axis, the heart-vascular endothelium axis, and the neurocardiac axis. According to the authors, reduced perfusion and congestion may contribute to intestinal barrier dysfunction and inflammation; bone-derived endocrine signals such as osteoprotegerin and osteocrin may influence cardiovascular remodeling; endothelial dysfunction is both a marker and mediator of disease progression; and autonomic imbalance remains central to heart failure pathophysiology. The review also argues that naturally occurring disease in dogs offers advantages over simplified experimental systems because these patients develop chronic, spontaneous disease within an intact physiologic lifespan. (mdpi.com)

Outside this paper, parts of that framework are already taking shape in the literature. Prior work has described gut dysbiosis and metabolic reprogramming in canine heart disease, including in myxomatous mitral valve disease, and a pilot study comparing dogs with congestive heart failure and healthy controls explored whether microbiome disruption may parallel observations from human heart failure research. Other recent veterinary literature has also widened the lens beyond a simple heart-kidney dyad, including a case report describing reversible cardio-renal-cerebral syndrome in a dog. Taken together, those reports suggest the review is less a radical break than an attempt to unify emerging threads into a single clinical and translational model. (frontiersin.org)

The paper’s forward-looking element is its emphasis on regenerative and organelle-based therapies. The authors discuss mesenchymal stem cell therapy and mitochondrial transplantation as examples of interventions that could act across inflammatory, endothelial, metabolic, and autonomic pathways. That aligns with broader translational cardiology discussions in veterinary medicine, where naturally occurring disease in dogs is increasingly framed as a bridge between laboratory discovery and human clinical application. Still, the surrounding literature also makes clear that translational promise does not equal near-term clinical readiness, and robust trial design will matter if these approaches are to move beyond concept. (mdpi.com)

Why it matters: For veterinarians, this reframing could influence both case management and research priorities. In practice, it supports more deliberate surveillance for renal compromise, gastrointestinal effects, nutritional and metabolic shifts, vascular dysfunction, and broader systemic inflammation in dogs with heart failure. In research, it may encourage biomarker panels and therapeutic studies that measure outcomes beyond cardiac output or echocardiographic change alone. That could be especially relevant in common canine conditions such as MMVD and DCM, where progression is often shaped by comorbidities, treatment effects, and whole-body adaptation, not just cardiac mechanics. (pmc.ncbi.nlm.nih.gov)

There’s also a translational message here for the profession. The review positions canine patients not simply as recipients of ideas borrowed from human cardiology, but as contributors to a two-way research model. That fits with broader One Health thinking in cardiovascular intervention research, which argues that dogs with naturally occurring disease can provide clinically relevant safety and efficacy insights that are difficult to reproduce in reductionist models. For veterinary teams, that may strengthen the field’s role in collaborative cardiology research while also emphasizing the ethical obligation to keep patient-centered benefit at the center of translational work. (pmc.ncbi.nlm.nih.gov)

What to watch: The next step is whether this conceptual shift leads to concrete changes, such as expanded diagnostic workups, multiorgan biomarker studies, and prospective trials testing regenerative or systems-based interventions in dogs with naturally occurring heart failure. Given that the review was published in late April 2026, the near-term signal will likely come from follow-up studies, conference presentations, and special-issue commentary rather than immediate guideline changes. (mdpi.com)